Articles
-
1 week ago |
onclive.com | Megan Hollasch |Ashling Wahner
Each research step that reveals patterns of activity with targeted therapies in endometrial cancer—such as metformin and temsirolimus (Torisel)—brings the field closer to developing increasingly effective and better-tolerated regimens that improve upon historical treatment results and quality of life (QOL) outcomes, according to Pamela T. Soliman, MD, MPH.
-
2 weeks ago |
onclive.com | Megan Hollasch
Putting an emphasis on immunohistochemistry (IHC) staining is top of mind as fam-trastuzumab deruxtecan-nxki (Enhertu, T-DXd) sits alongside tisotumab vedotin-tftv (Tivdak) as options in the second-line cervical cancer setting. Unlike the tissue factor–directed antibody-drug conjugate (ADC), the HER2-targeted ADC does not hold an all-comer indication and is only applicable for a select few patients.
-
2 weeks ago |
onclive.com | Megan Hollasch
CommentaryArticleApril 7, 2025Fact checked by:Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.
-
2 weeks ago |
onclive.com | Ashling Wahner |Megan Hollasch
The use of immunotherapy in patients with colorectal cancer (CRC) is currently largely confined to those with microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) disease, although questions remain regarding the optimal sequencing of immuno-oncology (IO) agents with surgery in colon cancer management, and ongoing studies may find ways to enhance immunotherapy responses in the broader microsatellite-stable (MSS)/MMR-proficient (pMMR) CRC population, according to Tanios S.
-
3 weeks ago |
onclive.com | Megan Hollasch
CommentaryArticleMarch 28, 2025Fact checked by:Gregory Roloff, MD, highlights ongoing frontline TKI research in Ph-positive ALL and why he uses a newer-generation TKI over imatinib.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →